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Abstract
Background: Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor
of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of
solid tumor including recurrent low-grade serous ovarian carcinoma (LGSOC). However, the long-term prognosis of
patients who receive selumetinib, as well as the late toxicity of the agent, have not yet been described.
Case Presentation: In this case report, we present a patient with recurrent LGSOC with KRAS mutation whose
tumor has not progressed and who has maintained a good general condition without severe toxicities following
treatment with selumetinib for more than 7 years. Next generation sequencing of her tumor revealed a G12V
mutation in KRAS. MAPK signaling inhibition plays a role in the biology of LGSOC.
Conclusions: Although biomarkers have yet to definitively define patients with LGSOC who are likely to respond to
therapy, exploration of specific alterations should be pursued in an excersie to develop a reliable companion
diagnostic test.
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Background
Serous carcinoma is the most common histological type
of ovarian cancer accounting for 70–80 % of all new
diagnoses. Evaluation of the molecular biology of high-
grade serous ovarian cancer (HGSOC) describes a dis-
ease associated with frequent P53 alterations, including
hemizygous loss, mutation, or amplification. The natural
history of HGSOC has been well documented and des-
pite significant improvements in surgical and adjuvant
treatment options, the number of patients cured has al-
tered very little over the last two decades. International
Federation of Gynecology and Obstetrics (FIGO) grading
(grades 1, 2, and 3) has also been a well-documented
prognostic factor for many of its histological subtypes.
However, investigation in the early 1990’s suggested that
low-grade serous ovarian cancer (LGSOC) could be
most reliably identified through a bivariate classification
(low and high). Further, patients with LGSOC appeared
to have a much different natural history. [1] For in-
stance, several studies have documented that LGSOC is
not as sensitive to cytotoxic chemotherapy relative to its
HGSOC counterpart but it is associated with much longer
expected overall survival [2, 3]. In addition, molecular
and genomic studies have shown that LGSOC appears to
have a higher frequency of functional estrogen (ER) and
progesterone receptor (PR) expression, KRAS or BRAF
mutations, a higher frequency of expression of active
mitogen-activated protein kinase (MAPK), and a lower
frequency of TP53 mutations than does HGSOC [4–7].
Selumetinib is a potent, selective, orally available, and
non-ATP competitive small molecule inhibitor of
mitogen-activated protein kinase kinase 1/2 (MEK1/2)
that has demonstrated single agent activity (objective re-
sponses) in a number of solid tumor including recurrent
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LGSOC [8, 9]. Herein, we present the clinical experience
of a woman with chemo- and hormonally-refractory re-
current LGSOC associated with a KRAS mutation whose
tumor has continually responded to selumetinib for more
than 7 years.
Case presentation
A 40-year-old woman with bilateral ovarian masses
was found at laparotomy to have a suspected ovarian
malignancy in October 1997. Surgical extirpation in-
cluded supracervical hysterectomy, bilateral salpingo-
oophorectomy, appendectomy, and staging biopsies.
The pathology was confirmed as a low-grade papillary
serous carcinoma of the ovary arising from a tumor
of low malignant potential in both ovaries with
microscopic metastatic implants in the omentum and
peritoneal surfaces. She was staged as FIGO Stage
IIIA and was treated with post-operative intravenous
paclitaxel (175 mg/m2) and carboplatin (AUC 5, PC)
for six cycles.
She did well until October 2005, when the patient’s
serum cancer antigen 125 (CA125) level was found to be
increased and imaging studies showed recurrent periton-
eal tumor. Biopsy confirmed recurrent LGSOC and she
underwent a secondary cytoreduction. Final pathology
also revealed ER and PR expression. Unfortunately, the
distribution of her recurrent disease precluded complete
surgical resection, leaving measurable disease in the
small bowel mesentery. She was treated adjuvantly with
nine cycles of PC achieving stable disease as her best re-
sponse. Due to neuropathy, fatigue and marrow exhaus-
tion she was not able to undergo further PC treatment.
She was then treated with letrozole, an aromatase inhibi-
tor, at a dose of 2.5 mg daily for 19 months. In May
2008, the patient’s imaging studies showed unequivocal
progression of a left upper quadrant lesion, and the
letrozole was discontinued.
In consideration of additional therapeutic options and
clinical trials, we performed a mutational analysis of the
recurrent tumor by next generation sequencing (NGS)
[10]. This revealed a KRAS mutation (Fig. 1). Fortu-
nately, GOG-239, a phase II clinical trial of selumetinib
in patients with LGSOC became available at this time, to
which she enrolled in June 2008. Selumetinib was ad-
ministered orally at a dose of 50 mg twice daily. A com-
puterized tomography (CT) scan was performed in
February 2009, and no new implants, ascites, masses or
adenopathy were seen in the abdomen or pelvis. The im-
pression was that there were stable implants. An implant
close to the hepatic flexure of the colon had a measure-
ment of 1.8 cm (Fig. 2a). Subsequent CT imaging scan
done in June 2009 showed sufficient change in her
measurable disease, including the previous hepatic
flexure implant (0.9 cm, Fig. 2b) to register a partial
response. She has continued on this therapy nearly un-
interrupted since. Most of her multiple recurrent lesions,
which were frequently associated with calcific deposits
have lost their soft tissue component and/or cystic
nature. Concern for lack of active disease, she has subse-
quently undergone several PET-CT images reveal FDG-
avid implants. In addition, tumor growth was observed
following two treatment breaks required for care of
other medical issues unrelated to disease or therapy. Re-
markably, reinitiation of selumetinib resulted in tumor
implant size reduction and for one lesion, resolution.
Our patient has experienced mild adverse events over
the many years of therapy. Most notable were intermit-
tent rashes (maximum grade 2) at anatomically disparate
areas, such as the trunk, chest, and eyelids, each of
which were treated conservatively with antibiotic oint-
ments and topical antihistamines. She has also experi-
enced grade 1 stomatits, intermittently. Of most notable
effect, she experienced de-pigmentation of her hair (now
blonde) and a birthmark on her right arm (no longer
visible). During the duration of her treatment the formu-
lation of selumetinib administered was changed from a
daily sachet (“mix and drink”, 100 mg BID) to tablets
(50 mg BID). Initially, this patient’s adverse events did
increase in frequency and intensity during the transition,
although they did not require discontinuation of the
therapy and further administration was not compro-
mised. Continuous monitoring for MEK-related cardio-
vascular, ophthalmological and metabolic dysfunctions
are ongoing.
Discussion
We present an unusual patient with recurrent LGSOC
with a KRAS mutation (G12V) whose tumor has not
progressed and who has maintained a good general con-
dition without severe toxicities by means of treatment
with selumetinib, a MEK inhibitor, for more than 7 years.
We believe she is the longest continuously treated pa-
tient with MEK-therapy under any indication.
As mentioned, this patient continues to participate
in GOG-239, a phase II trial of selumetinib in women
with recurrent, measurable LGSOC. Farley et al. re-
cently reported the results from this trial, and demon-
strated an overall response rate was 15 %, median
progression-free survival was 11 months (interquartile
range [IQR] 3.6–15.9) [9], and the median follow-up
time in patients who survived was 21 months (IQR
17–30). At the time of the publication (reflecting infor-
mation gathered until database lock), nine patients (17 %)
had been on therapy for more than 15 months.
LGSOCs typically have an indolent course with recur-
rences developing over many years, but eventually these
tumors develop intra-abdominal carcinomatosis, which
proves to be fatal, and LGSOC has been recognized as
Takekuma et al. Gynecologic Oncology Research and Practice  (2016) 3:5 Page 2 of 5
more chemoresistant than HGSOC [2, 3]. In 2008,
Schmeler et al. reported their experience with 25 pa-
tients with LGSOC treated with neoadjuvant chemother-
apy for inoperable disease at diagnosis; all patients were
treated with a platinum-based regimen, and only one
(4 %) experienced a complete response, while none had
a partial response, 21 had stable disease, and two (8 %)
had progressive disease [2]. In 2009, Gershenson et al.
published an analysis of 58 patients with recurrent
LGSOC in which the overall response rate was 3.7 %;
dividing the regimens by platinum-status, the response
rate was 4.9 % in platinum-sensitive tumors and 2.1 % in
platinum-resistant tumors, but that difference did not
reach statistical significance (p = 0.63) [3]. Since the
response rate of LGSOC to conventional treatment is
extremely poor, investigation into new therapeutic ap-
proach is urgently needed.
The clinical efficacy of hormonal therapy for LGSOC
is modest. A 2012 report from the M.D. Anderson
Cancer Center documented an overall response rate
and stable disease rate of 9 and 62 %, respectively
[11]. There was a statistically significant relationship
Fig. 2 Computerized tomography (CT) scans showing a decrease in an implant close to the hepatic flexure of the colon after the patients have
started taking selumetinib since June 2008
Fig. 1 Detection of a somatic KRAS mutation (c.35G > T; p.G12V) in DNA extracted from micro-dissected tumor cells from the patient with
recurrent low-grade serous carcinoma. DNA extracted from micro-dissected adjacent stromal cells was used as normal control. Sequencing
chromatograms were generated using PCR Sanger sequencing with AB3730XL sequencer
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between response and platinum-status in terms of both
overall response rate (ORR, 13.5 % vs 2.7 %) and time to
progression (TPP, 8.9 vs 5.7 months, P = 0.003).
The mitogen-activated protein kinase (MAPK), also
known as extracellular signal-regulated protein kinase
(ERK), is a downstream target of RAS, RAF, and MAP/
ERK kinase and is crucial for transduction of growth
signals from several key growth factors, cytokines, and
proto-oncogenes [12]. Mutations or overexpression of
components, including KRAS and BRAF, in the MAPK
pathway leads to constitutive activation of MAPK by
phosphorylation. Activation of MAPK in turn activates
downstream protein kinases, nuclear proteins, and
transcription factors [13], which may contribute to the
development of various tumors [14].
MEK is an attractive therapeutic target, as it lies
downstream of multiple activators of the pathway. As
such, selumetinib would be considered to have its great-
est effects on tumors harboring RAS or BRAF activating
mutations. While activating RAS mutations have been
documented as a frequent event in serous borderline
tumors and LGSOC, [14–16] there has been poor correl-
ation between response to selumetinib and RAS or BRAF
mutation. Of interest, G12D and G12V are the two most
common KRAS mutations. However, their downstream
signaling is not completely the same. G12D variant
signals primarily through PI3K, JNK, p38, and FAK
signaling pathways [17, 18] but signals less through the
RAF/ERK pathway. Furthermore, G12D causes constitu-
tive PI3K/mTOR activity [18]. One the other hand, the
G12V variant signals predominantly through MAPK
signaling cascade but has lost the ability to bind to and
signal through PI3K [18]. Thus, we speculate that tumor
cells with G12V mutation will be more sensitive to MEK
inhibitor while those with G12D will require inhibitors
targeting both MEK and PI3K pathways. Alternatively,
additional mutation(s) in the tumor cells may contribute
to the sensitivity to selumetinib. Using low passage
(10X) whole genome sequencing, we have identified 9
additional potential somatic missense mutations (Table 1).
Most of the amino acid changes have no predictive func-
tional impact on the protein function except USP45 gene.
USP45 encodes an ubiquitin-specific protease, which may
modulate the MAPK pathway [19]. Thus, further investi-
gation is warranted. In addition, despite intensive studies,
the genetic and molecular basis for resistance to selumeti-
nib remains poorly understood. Grasso et al. reported that
p70 S6 kinase and its downstream target ribosomal pro-
tein S6 may be biomarkers of resistance to selumetinib in
colorectal cancer [20].
Conclusions
Treatment of LGSOC continues to evolve as new targets
emerge with functional consequence. Our case report and
others point to MAPK signaling as one pathway with
therapeutic viability. Currently, two prospective, random-
ized phase III clinical trials of single agent MEK inhibitors
(binimetinib and trametinib, both versus physician’s
choice chemotherapy or hormones) are being conducted
in women with LGSOC (NCT01849874, NCT02101788).
Both trials require central pathology review to confirm
the diagnosis and allow MEK inhibitor cross-over on pro-
gression of control therapy. Although recruitment to the
former, using binimetinib, was recently halted due to an
unfavorable planned futility assessment, a comprehensive
review of the final results from these trials will be import-
ant to determine the role MEK inhibitors in this rare
disease.
Patient consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Table 1 Low 185 passage whole genome sequencing

















CCDC110 P209Q 7 9 44 0 8 0 Neutral
FAT1 Q2933P 6 6 50 0 6 0 Neutral
PCDHGA1 A443T 7 6 54 0 5 0 Neutral
USP45 K67E 6 6 50 0 5 0 Medium
RP1L1 Q1861P 5 7 42 0 9 0 Neutral
PLBD1 L25delL 7 7 50 0 9 0 Neutral
KRAS G12V 8 11 42 0 9 0 Medium
KRT84 I206V 11 4 73 0 3 0 Neutral
ADAMTS17 N1094S 6 7 46 0 8 0 Neutral
ADAM33 M764T 7 9 44 0 4 0 Low
Takekuma et al. Gynecologic Oncology Research and Practice  (2016) 3:5 Page 4 of 5
Competing interests
RLC has received clinical trial research grants from AstraZeneca. KKW and MT
declare no competing interests.
Authors’ contributions
All authors contributed to the design, data acquisition, data analysis and
interpretation and manuscript preparation (writing and assembly). All authors
read and approved the final manuscript.
Author details
1The Division of Gynecology, Shizuoka Cancer Center, Shizuoka 411-8777,
Japan. 2Department of Gynecologic Oncology & Reproductive Medicine,
University of Texas, M.D. Anderson Cancer Center, 1155 Herman Pressler Dr.,
CPB6.3590, Houston, TX 77030, USA.
Received: 16 January 2016 Accepted: 27 April 2016
References
1. Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, et al.
Comparison of the clinical behavior of newly diagnosed stages II-IV
low-grade serous 213 carcinoma of the ovary with that of serous
ovarian tumors of low malignant potential that recur as low-grade
serous carcinoma. Gynecol Oncol. 2007;105:625–29.
2. Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, et al.
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or
peritoneum. Gynecol Oncol. 2008;108:510–4.
3. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al.
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gynecol Oncol. 2009;114:48–52.
4. Singer G, Oldt III R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al.
Mutations in BRAF and KRAS characterize the development of low-grade
ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484–6.
5. Singer G, Kurman RJ, Chang HW, Cho S, Shih IM. Diverse tumorigenic
pathways in ovarian serous carcinoma. Am J Pathol. 2002;160:1223–8.
6. Hsu CY, Bristow R, Cha M, Wang B, Ho CL, Kurman RJ, et al. Characterization
of active mitogen-activated protein kinase in ovarian serous carcinomas.
Clin Cancer Res. 2004;10:6432–6.
7. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of
p53 mutations separate ovarian serous borderline tumors and low- and
high-grade carcinomas and provide support for a new model of ovarian
carcinogenesis: a mutational analysis with immunohistochemical correlation.
Am J Surg Pathol. 2005;29:218–24.
8. Della Pepa C, Tonini G, Santini D, Losito S, Pisano C, Di Napoli M, et al. Low
grade serous ovarian carcinoma: from the molecular characterization to
the best therapeutic strategy. Cancer Treatment Rev. 2015;41:136–43.
9. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al.
Selumetinib in women with recurrent low-grade serous carcinoma of the
ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol.
2013;14:134–40.
10. Wong KK, Tsang YT, Deavers MT, Mok SC, Zu Z, Sun C, Malpica A, Wolf JK,
Lu KH, Gershenson DM. BRAF mutation is rare in advanced-stage low-grade
ovarian serous carcinomas. Am J Pathol. 2010;177(4):1611–7.
11. Gershenson DM, Sun CC, Lyer RB, Malpica AL, Kavanagh JJ, Bodurka DC, et al.
Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or
peritoneum. Gynecol Oncol. 2012;125:661–66.
12. Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer
therapy. Trends Mol Med. 2004;10:125–9.
13. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of
activation. Biol Cell. 2001;93:53–62.
14. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted
signal transduction inhibitor of MEK (MAPKK). Semin Oncol.
2003;30(5 Suppl 16):105–16.
15. Cuatrecasas M, Erill N, Musulen E, et al. K-ras mutations in nonmucinous
ovarian epithelial tumors: a molecular analysis and clinicopathological study
of 144 patients. Cancer. 1998;82:1088–95.
16. Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in
mucinous ovarian tumors. Cancer. 1997;79:1581–6.
17. Cespedes MV, Sancho FJ, Guerrero S, et al. K-ras Asp12 mutant neither
interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras
Val12. Carcinogenesis. 2006;27(11):2190–200.
18. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on
protein behavior: implications for signaling and clinical outcome. J Natl
Cancer Inst. 2012;104(3):228–39.
19. Yamashita M, Shinnakasu R, Asou H, Kimura M, Hasegawa A, Hashimoto
K, Hatano N, Ogata M, Nakayama T. Ras-ERK MAPK cascade regulates
GATA3 stability and Th2 differentiation through ubiquitin-proteasome
pathway. J Biol Chem. 2005;280(33):29409–19.
20. Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-Lopez L, Carballo-Santana
M, et al. Resistance to selumetinib (AZD6244) in colorectal cancer cell lines is
mediated by p70S6K and RPS6 activation. Neoplasia. 2014;16:845–60.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Takekuma et al. Gynecologic Oncology Research and Practice  (2016) 3:5 Page 5 of 5
